First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials

INTRODUCTION: Metastatic colorectal cancer (mCRC) is one of the most common cancers and the second leading cause of cancer worldwide. With the improvement of systemic and operative therapies, median overall survival (mOS) reached 30 months or longer. Here, we will review the use of the anti-vascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Arndt, Kirstein, Martha M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604573/
https://www.ncbi.nlm.nih.gov/pubmed/31579770
http://dx.doi.org/10.1515/iss-2018-0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604573/
https://www.ncbi.nlm.nih.gov/pubmed/31579770
http://dx.doi.org/10.1515/iss-2018-0012

Ejemplares similares